Singapore, Oct. 21 -- Samsung Biologics has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing.

Under this agreement, South Korean firms Samsung and Dinona will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.

Since its inception, the Samsung Biologics CDO business has been growing at a rapid pace with near 60 contracts signed in just two years. The business segment continues to expand its market reach through a cumulative track record of various biologics products beyond monoclonal antibodies and by ...